Results 161 to 170 of about 43,579 (203)

Vaccinating against cholera

Nursing Standard, 1990
Vaccination against cholera is being over-prescribed and may lead to a false sense of security.
openaire   +2 more sources

Stability of cholera and typhoid vaccines

Journal of Biological Standardization, 1979
Fluid plain and adsorbed and freeze-dried cholera and tyhpoid vaccines of different composition were examined for thermostability by potency testing (by active mouse protection tests) after exposure to 37 degrees C for 1, 2, 3, 4, 8 and 12 weeks. Loss of potency was evaluated by comparison with samples stored at 4 degrees C.
J. Zsidai, I. Joó
openaire   +3 more sources

No Vaccines in the Time of Cholera [PDF]

Science, 2010
The threat of a major cholera epidemic looms over flood-stricken Pakistan. So why is a new, relatively cheap vaccine unlikely to make a difference?
openaire   +1 more source

Cholera vaccines for the developing world

Human Vaccines, 2008
Cholera remains as a global public health threat affecting most of the developing world. In endemic areas, young children are most affected. Outbreaks are reported increasingly from more countries. Improvements in water and sanitation may be the mainstays of cholera prevention but in the short term, vaccines provide an alternative in cholera control ...
Luis Jodar, John D. Clemens, Jacqueline L. Deen, Anna Lena Lopez   +3 more
openaire   +3 more sources

Assay of cholera vaccine potency

Journal of Biological Standardization, 1977
The Feeley-Pittman active mouse protection test was examined as a method of estimating the potency of cholera vaccines in the laboratory before their administration in the field. With strict standardization of conditions, it was found to give reproducible estimates both within and between laboratories.
Jennifer A. Mumford, Annette W. Ford, P.R. Richer   +2 more
openaire   +3 more sources

Bivalent Cholera and Typhoid Vaccine

Drugs, 1999
The live attenuated vaccine strains Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a can be combined into an oral bivalent vaccine without compromising the immunogenicity of the individual vaccine strains. Seroconversion rates of 87 to 94% for Inaba vibriocidal antibodies and 72 to 91% for anti-S.
Stuart Noble, Rachel H. Foster
openaire   +3 more sources

The first British reference preparations of cholera vaccine (Inaba) and of cholera vaccine (Ogawa)

Journal of Biological Standardization, 1977
Abstract An international collaborative study was undertaken to assess the suitability of a preparation of cholera vaccine (Inaba) and one of cholera vaccine (Ogawa) to serve as British reference preparations. Eight laboratories participated in the study.
Valerie Seagroatt, Annette W. Ford
openaire   +3 more sources

Molecular design of cholera vaccines

Vaccine, 1992
Cholera is still a serious public health problem in developing countries, particularly those in tropical regions. This has stimulated considerable research into the molecular analysis of pathogenesis resulting in the identification of a number of critical components required for both colonization of the gut mucosa and the disease symptoms.
openaire   +3 more sources

Embracing Oral Cholera Vaccine — The Shifting Response to Cholera

New England Journal of Medicine, 2014
Despite evidence of the safety and efficacy of oral cholera vaccines, they were not included in the prevention package during the 2010 Haitian cholera epidemic. But some major obstacles to the use of OCVs in cholera outbreaks have since been overcome.
Vanessa Rouzier, Jean W. Pape
openaire   +3 more sources

Cholera vaccines

The Lancet Infectious Diseases, 2007
openaire   +2 more sources